Jan Zitko
Overview
Explore the profile of Jan Zitko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nawrot D, Koutnikova B, Jandourek O, Konecna K, Novak M, Paterova P, et al.
Chem Biol Drug Des
. 2025 Jan;
105(1):e70030.
PMID: 39835639
Infectious diseases, including bacterial, fungal, and viral, have once again gained urgency in the drug development pipeline after the recent COVID-19 pandemic. Tuberculosis (TB) is an old infectious disease for...
2.
Salam R, Bakker M, Krutakova M, Stefela A, Pavek P, Duintjer Tebbens J, et al.
Arch Pharm (Weinheim)
. 2025 Jan;
358(1):e2400423.
PMID: 39801251
The Takeda G protein-coupled receptor 5 (TGR5), also known as GPBAR1 (G protein-coupled bile acid receptor), is a membrane-type bile acid receptor that regulates blood glucose levels and energy expenditure....
3.
Pallabothula V, Abdalrahman N, Mori M, Fekri A, Jandourek O, Konecna K, et al.
Arch Pharm (Weinheim)
. 2024 May;
357(8):e2400171.
PMID: 38710636
This study presents an exploration of the chemical space around derivatives of 3-benzamidopyrazine-2-carboxamides, previously identified as potent antimycobacterial compounds with predicted binding to mycobacterial prolyl-transfer RNA synthetase. New urea derivatives...
4.
Kerda M, Slechta P, Jandourek O, Konecna K, Hatokova P, Paterova P, et al.
Future Med Chem
. 2023 Oct;
15(19):1791-1806.
PMID: 37877255
The development of novel antimicrobial drugs is an essential part of combatting the uprising of antimicrobial resistance. Proper hit-to-lead development is crucially needed. We present a hit-expansion study of -pyrazinyl-...
5.
Bouz G, Slechta P, Jandourek O, Konecna K, Paterova P, Barta P, et al.
ACS Infect Dis
. 2023 Jul;
9(8):1674.
PMID: 37486740
No abstract available.
6.
Nawrot D, Bouz G, Jandourek O, Konecna K, Paterova P, Barta P, et al.
Eur J Med Chem
. 2023 Jul;
258:115617.
PMID: 37423128
Tuberculosis is the number one killer of infectious diseases caused by a single microbe, namely Mycobacterium tuberculosis (Mtb). The success rate of curing this infection is decreasing due to emerging...
7.
Juhas M, Bachtikova A, Nawrot D, Hatokova P, Pallabothula V, Diepoltova A, et al.
Pharmaceuticals (Basel)
. 2023 Mar;
16(3).
PMID: 36986575
In the original publication [...].
8.
Bouz G, Slechta P, Jandourek O, Konecna K, Paterova P, Barta P, et al.
ACS Infect Dis
. 2022 Dec;
9(1):79-96.
PMID: 36577009
Apart from the SARS-CoV-2 virus, tuberculosis remains the leading cause of death from a single infectious agent according to the World Health Organization. As part of our long-term research, we...
9.
Pallabothula V, Kerda M, Juhas M, Jandourek O, Konecna K, Barta P, et al.
Biomolecules
. 2022 Nov;
12(11).
PMID: 36358911
Multidrug-resistant tuberculosis (MDR-TB) poses a significant threat to mankind and as such earned its place on the WHO list of priority pathogens. New antimycobacterials with a mechanism of action different...
10.
Juhas M, Bachtikova A, Nawrot D, Hatokova P, Pallabothula V, Diepoltova A, et al.
Pharmaceuticals (Basel)
. 2022 May;
15(5).
PMID: 35631406
Antimicrobial drug resistance is currently one of the most critical health issues. Pathogens resistant to last-resort antibiotics are increasing, and very few effective antibacterial agents have been introduced in recent...